Mutations in the novel serine/threonine WNK [With No lysine (= K)] kinases WNK1 and WNK4 cause PHAII (pseudohypoaldosteronism type II or Gordon's syndrome), a rare monogenic syndrome which causes hypertension and hyperkalaemia on a background of a normal glomerular filtration rate. Current animal models for PHAII recapitulate some aspects of the disease phenotype, but give no clues to how rapidly the phenotype emerges or whether it is reversible. To this end we have created an inducible PHAII transgenic animal model that expresses a human disease-causing WNK4 mutation, WNK4 Q565E, under the control of the Tet-On system. Several PHAII inducible transgenic mouse lines were created, each with differing TG (transgene) copy numbers and displaying varying degrees of TG expression (low, medium and high). Each of these transgenic lines demonstrated similar elevations of BP (blood pressure) and plasma potassium after 4 weeks of TG induction. Withdrawal of doxycycline switched off mutant TG expression and the disappearance of the PHAII phenotype. Western blotting of microdissected kidney nephron segments confirmed that expression of the thiazide-sensitive NCC (Na + -Cl − co-transporter) was increased, as expected, in the distal convoluted tubule when transgenic mice were induced with doxycycline. The kidneys of these mice also do not show the morphological changes seen in the previous transgenic model expressing the same mutant form of WNK4. This inducible model shows, for the first time, that in vivo expression of a mutant WNK4 protein is sufficient to cause the rapid and reversible appearance of a PHAII disease phenotype in mice.
INTRODUCTION
Hypertension affects one quarter of the world's industrialized population and presents a significant risk factor for stroke, heart disease and renal failure. For most individuals, their major factor for developing hypertension is the inheritance of multiple genetic risk alleles whose individual effects on BP (blood pressure) are small and modulated by gene-gene and gene-environment interactions. However, there are rare familial forms of hypertension that are inherited through a single mutant pressor gene. PHAII [pseudohypoaldosteronism type II; OMIM Online Mendelian Inheritance in Man) 145260] or Gordon's syndrome (PHAII) exemplifies one of these monogenic forms of familial hypertension and is caused by mutations that cause a gain-of-function in the thiazide-sensitive NCC (Na + -Cl − co-transporter) in the Abbreviations used: BP , blood pressure; CMV, cytomegalovirus; DCT, distal convoluted tubule; EGFP , enhanced green fluorescent protein; FISH, fluorescence in situ hybridization; MCS, multiple cloning site; NCC, Na + -Cl − co-transporter; PHAII, pseudohypoaldosteronism type II, pNCC, phosphorylated NCC; TG, transgene; TRE, tetracycline response element; WNK, With No lysine (= K); WT, wild-type.
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distal nephron of the kidney. The mutations involve either novel serine/threonine kinases that regulate the trafficking and phosphorylation of NCC, WNK1 and WNK4 [where WNK is With No lysine (= K)] [1, 2] or two recently identified genes thought to be involved in the ubiquitination of NCC [3] . Subjects carrying these mutations have salt-dependent hypertension and hyperkalaemia that is characteristically reversed by small doses of thiazide-type diuretics that block the enhanced NCC transporter activity [4, 5] . Previous use of transgenic and knock-in approaches have shown that expression of a mutant WNK4 protein in mice can mimic the human PHAII phenotype with mouse models showing elevated BP and hyperkalaemia [6, 7] . However, this is not a universal experience, and transgenic mice expressing the D561A WNK4 mutant in the distal nephron do not have a PHAII phenotype [8] . A recent report has also highlighted that transgenic overexpression of NCC in the mouse kidney does not cause a PHAII phenotype or even raise the BP [9] . There is also no data on how quickly a PHAII phenotype emerges when a mutant WNK4 protein is expressed in vivo and what happens to the phenotype when mutant protein expression ceases.
To address these issues we aimed to conditionally induce and reverse a PHAII phenotype by using a mouse carrying a TG (transgene) expressing the Q562E mutation in the WNK4 gene (referred to subsequently as WNK4 Q562E), the murine equivalent of the known human Q565E mutation of WNK4, using the Tet-On system [10] [11] [12] . The Tet-On system relies on a transactivator protein, rtTA, which is responsible for binding to a TRE (tetracycline response element) in the presence of the tetracyclinederivative, doxycycline. The rtTA is normally supplied as part of the Tet-On plasmid vector and delivered in trans, i.e. as a separate plasmid transfected into the target cell type bearing a pTRE2 plasmid. Alternatively, for in vivo work, the delivery is effected by crossing two animals, one carrying the pTRE2 response plasmid and the other the Tet-On for transactivation. However, in the model reported here the pTRE and rTA were expressed in a single expression cassette driving the WNK4 Q562E cDNA expression in the presence of doxycycline. Several transgenic mouse lines were created with this construct and all develop a typical PHAII phenotype of hypertension and hyperkalaemia when exposed to doxycycline, which completely reverses when the doxycycline is withdrawn. This shows that expression of the mutant WNK4 Q562E gene is sufficient to cause the emergence of a PHAII phenotype in 4 weeks and provides a useful reversible mouse model for this familial hypertension syndrome.
MATERIALS AND METHODS
RNA extraction and cDNA synthesis RNA was extracted from whole mouse kidney using TRIzol ® (Invitrogen), according to manufacturer's instructions, and only samples with a A 260 /A 280 ratio of at least 1.8 on a NanoDrop ® ND-1000 spectrophotometer (Thermo Scientfic) were processed. The cDNA was reverse-transcribed using Oligo (dT) primers (Invitrogen) and, SuperScript ® III Reverse Transcriptase (Invitrogen) using 1 μg of RNA, according to manufacturer's instructions.
Creation of the tetracycline-inducible WNK4 Q562E cDNA construct RNA isolated from homogenized mouse kidney was transcribed to synthesize mouse WNK4 cDNA. A 4117 bp WNK4 cDNA was then amplified by PCR, using forward 5 -AT-TATTACGCGTACCCAGCCGGTCTGCCTGTCAGGCAGCA-ACCTCCAG-3 and reverse 5 -ATTATTTCTAGAATTCTCG-AGGCCTTTCTCCTCAGTATTTTTATTGGTTGCTGTTGA-3 primers, 10 mM dNTP mix (Bioline), 2.5 units of Pfu Turbo ® Hotstart DNA polymerase (Agilent Technologies), 10× reaction buffer and 50 ng of template cDNA. An Mlu1 restriction enzyme site was incorporated into the 5 end of the forward primer and XhoI and Xba1 restriction enzyme sites into the 5 end of the reverse primer. Thermal cycling was: one cycle at 95
• C for 5 min, 35 cycles of 95
• C for 30 s, 68
• C for 1 min and 72
• C for 5 min. The product was purified by a QIAquick ® PCR Purification Kit (Qiagen) and ligated into the MCS (multiple cloning site) of a compatible restriction digested pTRE2 vector (Clontech). This plasmid was then subjected to site-directed mutagenesis PCR using a QuikChange ® Site-Directed Mutagenesis Kit (Qiagen). Forward (5 GAGCCAGAGGCTGACGAGCATCAATCCTTCC 3 ) and reverse (5 GGAAGGATTGATGCTCGTCAGCCTCTGGCTC 3 ) primers were used to introduce the C>G substitution creating the Q562E mutation. The final WNK4 Q562E cDNA was downstream of the enhancerless minimal CMV (cytomegalovirus) promoter (P mini CMV) fused to an upstream TRE. The entire miniCMV TRE WNK4 Q562E cDNA was excised using XhoI, and cloned in-frame and downstream of the EGFP (enhanced green fluorescent protein) sequence STOP codon and into the XhoI restriction site within the MCS of the 4.7 kb pEGFP-C1 vector (Clontech). Using the Tet-On plasmid (Clontech) and forward (5 -GTTGACATTGATTATTGACTAGTTATTAATA-GTAATCAATT-3 ) and reverse (5 -AAGCTTGGTCGA-GCTGATACTTCCCGTCCGCCAGGGGACAT- 3 ) primers, a 2169 bp fragment, consisting of an upstream enhancerless CMV promoter (P mini CMV), fused to an rtTA sequence with a downstream poly(A) tail was produced by PCR. The PCR product was checked on a 1 % (w/v) agarose gel and purified using a Quick Spin TM Column (Roche). This rtTA-fragment was then cloned into a compatible Sal1 restriction site upstream of the TRE WNK4 Q562E cDNA, within the modified pEGFP-C1 plasmid. Since EGFP expression has been shown to cause cardiomyopathy in mice [14] , the CMV sequences driving EGFP expression were excised as a 3460 bp fragment using AgeI and DraIII enzymes (New England Biolabs). This final linearized WNK4Q562E TG construct was microinjected into oocytes ( Figure 1 ).
Generation of transgenic mice
All animal procedures had local ethical committee approval and were carried out in accordance with UK Home Office regulations. C57BL/6J and CBA/J mice (both from Charles River Laboratories) were crossed to generate B6CBA/F1 hybrid mice to allow the harvesting of single-cell B6CBA/F2 fertilized eggs for manipulation in vitro. Transgenic mice were generated by pronuclear microinjection of the linearized WNK4 Q562E cDNA TG construct into B6CBA/F2 single-cell mouse embryos according a standard method [15, 16] . Following pronuclei fusion, zygotes were allowed to divide to a two-cell stage in vitro and then implanted into pseudopregnant females. The resulting pups were genotyped by PCR to identify transgenic founders (see below).
Genotyping of mice
Transgenic founders were identified using primers to distinguish between WT (wild-type) genomic WNK4 sequence and the WNK4 TG. Forward (5 -GAAGTGGAGGCACTACAGACAC-3 ) and reverse (5 -CTGCCACTCAGAGAGT TCCTTC-3 ) primers were designed to hybridize to WNK4 exons 17 and 18 respectively. This amplified TG cDNA and WNK4 genomic sequences as separate PCR products: a 221 bp and a The presence of the Q562E mutation was confirmed in the same gDNA samples by exon 7-specific PCR and Hin4I digestion to produce RFLP (restriction-fragment-length polymorphism) products. Founders 1-6 contain the WNK4 Q562E cDNA TG. A 100 bp ladder is on the left in both gels.
larger 371 bp product due to the 150 bp intron 17 ( Figure 2A ). The Q562E mutation in transgenic mice was confirmed by PCR and restriction digest of the products since the Q562E mutation creates a Hin4I restriction site. Exon 7 was PCR amplified using forward (5 -GAGAACGGGTTGCTGCTATC-3 ) and reverse (5 -TTGATGAGTAGCTGGCATGG-3 ) primers and the 204 bp product digested with Hin4I and run on a 2 % (w/v) agarose gel. WT mice contained only the 204 bp product from genomic DNA, whereas transgenic mice showed additional bands (153, 32 and 19 bp) reflecting Hin4I digestion of the 204 bp PCR product derived from the TG WNK4 Q562E cDNA ( Figure 2B ).
TG copy number determination
The number of WNK4 Q562E cDNA TG copies in each line was determined using a real-time TaqMan ® qPCR assay. Primer and probe sets were used to detect WNK4 cDNA TG and the KCNJ1 control gene, which encodes the inwardly-rectifying potassium channel protein ROMK. Genomic DNA extracted from WT and transgenic founder mice was quantified using NanoDrop ® to produce a standard of 100 ng/μl and diluted to give DNA standards from 100 to 0.1 pg/μl. The 1 μl triplicate samples of each standard, together with appropriate positive, WNK4 Q562E construct cDNA, and negative non-template controls were subjected to realtime qPCR (quantitative PCR) using a ABI Prism 7700 machine (Applied Biosystems) and appropriate primer/probe combinations. For the KCNJ1 control gene the expression primer/probe Mm00444727_s1 (Locus NM 019659; Applied Biosystems) was used to amplify a 126 bp fragment of exon 2. To detect the WNK4 Q562E cDNA TG, probe Mm00841400_m1 (Locus NM 175638; Applied Biosystems) was used to selectively amplify an 83 bp fragment spanning exons 4-5 of the cDNA. For KCNJ1, the mean fluorescence threshold, C t , was plotted semi-log against control genomic DNA in the dilution series to give a standard curve from 100 ng-0.1 pg. This was repeated for the WNK4 Q562E cDNA TG and the shift in the two curves, C t , was used to estimate the copy number of WNK4 Q562E TGs integrated into each founder genome as 2×(2 Ct ).
Breeding of transgenic lines
WNK4 Q562E transgenic founders were bred with non-transgenic WT B6CBA mice to generate three individual lines. Hemizygotes for each line were identified by PCR (see below) and crossed to generate homozygotes. Transgenic homozygotes (TG/TG) identified by PCR (see below) were then crossed to establish homozygous lines of animals for phenotyping studies. The zygosity of hemi-against homo-zygotes was determined by a real-time quantitative TaqMan ® assay using the above mouse WNK 4 probe and primers (Mm00841400_m1; Applied Biosystems). TG/TG mice have twice the amount of TG cDNA as their hemizygote counterparts, which was detected by the one C t cycle difference between them. TaqMan ® assays were run in triplicate and genomic DNA from non-transgenic mice were used as negative controls. Transgenic homozygotes in each of the three lines were interbred to generate the final lines: low TG, mid TG and high TG copy number mice. Homozygotes from each line were used for phenotyping.
Gene expression assays
Kidney RNA was extracted from mice and reverse transcribed as above (on or off doxycycline) The resulting cDNA was probed using primer/probe sets to quantify expression of WNK4 (Mm00841400_m1), SLC12A3 (Mm00490213_m1) and KCNJ1 (Mm01173990_m1) (all from Applied Biosystems). Expression levels were normalized to the expression of the β-actin housekeeping gene, using the primer/probe set Mm 00607939_s1(Applied Biosystems).
Animals and treatments
Age-matched male and female WNK4 Q562E transgenic and control B6CBA mice (WT/WT) were placed on either normal mouse chow pellets (containing 0.3 % NaCl/g of diet) or the same diet containing doxycycline at 200 mg/kg of body weight (custom-made by Bio-Serv). Mice were usually phenotyped at 8-12 weeks of age and all phenotyping was carried out within dedicated facilities at the University Of Cambridge School Of Clinical Medicine, in accordance with UK Home Office Regulations.
Blood collection and plasma electrolyte analysis
Blood (200 μl) of was collected by capillary action into lithiumheparin-coated Microvette ® CB300 tubes (Sarstedt) from lateral tail vein bleeds and centrifuged at 18 000 g for 10 min in a bench top Beckman Coulter Microfuge-18 centrifuge (http://www.beckmancoulter.com). Approximately 75-100 μl of the supernatant was then removed and analysed for electrolytes or stored at − 20
• C for later analysis. Plasma K + levels were analysed using a Dade Dimension RXL Chemistry Analyser (Department of Clinical Biochemistry, Cambridge, U.K.).
BP measurements
Carotid artery BP was recorded from anaesthetized mice using previously published methods [17] .
Kidney tubule microdissections
Mice were anasthetized and their kidneys cannulated and perfused with buffer containing recombinant collagenase (Liberase; Roche Diagnostics) for 15 min and individual nephron segments were identified and dissected as detailed previously [17] .
Western blot analysis
Proteins extracted from the microdissected nephron segments were separated by SDS/PAGE (8 % gel) and transferred on to a PVDF membrane (Amersham Biosciences). The PVDF membrane was probed with an appropriate antibody, dissolved in 5 % (v/v) TBS (Tris-buffered saline) + Tween 20/Marvel milk powder, at 4
• C overnight to visualize either: β-actin (housekeeping protein), NCC protein or pNCC (phosphorylated NCC) at Thr 58 . The antibodies used were polyclonal goat anti-(mouse β-actin) antibody (Abcam) at 1 μg/ml, polyclonal rabbit anti-(rat NCC) antibody (Chemicon) at a dilution of 1:2000, and polyclonal sheep anti-(human pNCC Thr 60 ) antibody (kindly provided by Professor Dario Alessi, MRC Phosphorylation Unit, University of Dundee, Dundee, Scotland, U.K.) at a concentration of 2 μg/ml. Blots were visualized using ECL (enhanced chemiluminescence) reagent (Amersham Biosciences) according to the manufacturer's instructions.
FISH (fluorescence in situ hybridization)
Lymphocytes were expanded from a total cell population obtained from homogenized mouse spleen tissue, using 0.05 mg/ml lipopolysaccharide (Sigma-Aldrich) in RPMI medium (SigmaAldrich) with 10 % (v/v) fetal calf serum (Invitrogen) and the cells arrested with 0.1 μg/ml of KaryoMAX ® Colcemid TM Solution (Invitrogen). The cells were then processed for FISH using a published protocol [18] , and the slides scored for the presence or absence of fluorescence and chromosomes karyotyped according to the standard method [19, 20] .
Statistical analyses
Results are presented as + − S.E.M unless stated otherwise. Group differences were carried out using ANOVA with post-hoc testing or a Mann-Whitney U test as appropriate, using GraphPad Prism version 5 software. Significance was set at P < 0.05.
RESULTS

Generation of WNK4 Q562E transgenic mice
A total of 13 mice were successfully born after pronuclear microinjection of the cloned and linearized WNK4 Q562E TG construct into recipient mouse oocytes. The genotyping PCR ( Figure 2 ) showed that six of these 13 founder (F 0 ) mice had the WNK4 Q562E TG detectable in their genome. The TG copy number in these founders was measured by real-time TaqMan ® PCR with KCNJ1 as the reference gene. The C t for amplification of this gene in serial dilutions of a mouse genomic DNA standard was determined. Similar curves were generated using a WNK4 TaqMan ® probe set against serial genomic DNA dilutions from each founder mouse and are plotted on the same KCNJ1 curve. From the difference in cycle number, C t , between the WNK4 and KCNJ1 curves copy number was estimated for each founder (Table 1) . From these results, three founders were taken forward to produce lines containing low-(founder 2), medium-(founder 5) or high-(high founder 6) TG copy number. During the breeding of these lines the zygosity status of the offspring was established by real-time TaqMan ® PCR assay for the WNK4 Q562E TG. Homozygote mice from these three lines were then used in further phenotyping.
TG expression levels
To confirm TG activation whole kidney levels of WNK4 RNA transcript were measured by qPCR in mice from each of the 3 lines before and after 1 month on a doxycycline-containing diet (Figure 3) . The levels of WNK4 RNA in non-transgenic mice were not affected by the doxycycline diet itself, but it caused a 16-, 87-and 151-fold increase in WNK4 RNA levels in the low-, middle-and high-TG copy number lines respectively. These levels reversed after a further 1 month on the doxycycline-free control diet to pre-stimulation levels. The baseline levels of WNK4 RNA were not different between the non-transgenic control mice (WT/WT) and the low-TG copy number line, but were ∼2-fold higher in the mid-and high-expressing lines, suggesting some leak from the TG due to the high copy numbers (Figure 3 ). The levels of transcript for NCC (Scl12a3) in the kidney were not affected by exposure to doxycycline or different in any of the lines compared with non-transgenic control mice (Supplementary Figure S1 at http://www.clinsci.org/cs/124/cs1240701add.htm).
FISH
To confirm chromosomal integration of the TG, FISH was performed on the low TG copy number mouse. This confirmed integration on the homologue of chromosome 4 ( Figure 4) . The fluorescent probe did not hybridize to the non-transgenic mouse metaphase chromosomes, confirming the specificity of the probe for the WNK4 Q562E TG.
BP and plasma K + measurement
An elevated plasma K + concentration is a striking feature of the PHAII phenotype that distinguishes it from other monogenic hypertension syndromes. In parallel with the WNK4 Q562E TG activation, all three transgenic lines showed significantly elevated plasma K + levels after 1 month on the doxycycline-containing diet compared with mice fed on the control diet ( Figure 5A) . Silencing of the TG by a further month on the doxycycline-free diet led to normalization of the elevated plasma K + levels in all three lines ( Figure 5A ). In a parallel fashion the low-and mid-TG copy number lines had a significant elevation of their mean arterial BP of ∼20 mmHg after being dosed with doxycycline for 1 month ( Figure 5B) . However, the increase did not reach statistical significance in the high-expressing line. Dosing for a further month on a doxycycline-free diet returned the BP to the levels observed in the non-transgenic controls ( Figure 5B ).
Western blot analysis of NCC expression from microdissected kidney tubules
Expression of total NCC and pNCC protein was studied in microdissected tubules from the low-TG copy number line only. Protein staining for NCC and pNCC was only detected in the microdissected tubules from the DCT (distal convoluted tubule) and both were increased ∼1.5-2-fold in low-TG copy number mice after 1 month on the doxycycline-containing diet (Figure 6 ). 
DISCUSSION
The results of the present study show that it is possible to create an inducible model of Gordon's syndrome (PHAII) by expressing a mutant WNK4 protein in vivo under a Tet-On system. The previous work has shown that mice constitutively expressing WNK4 Q562E or another mutant as a knock-in (D561A + / − ) have hypertension and hyperkalaemia [6] . TG expression of the same D561A mutation in another mouse model, however, did not produce a PHAII phenotype [8] , and it is not clear why these mouse models behave differently. Differences in the genetic background of the mice used may be important. Another factor that has emerged in some WNK1 mouse models of Gordon's syndrome (PHAII) is compensatory changes to other parts of the distal nephron to explain the lack of the expected phenotype [21] . For example, down regulation of the epithelial sodium channel, ENaC, in the collecting ducts can ameliorate increased NaCl retention in the DCT [21] . In fact, the degree to which the plasma K + and BP was raised in the constitutive WNK4 Q562E transgenic mouse was lower than the >20 mmHg increase in mean BP and the ∼1 mmol/l increase in plasma K + levels we observed in our present inducible model. However, such a comparison of plasma K + levels is problematic because of potentially important differences in variables such as the venepuncture site, genetic background and diet of the mice. However, if these differences Figure 6 Western blots of microdissected kidney tubular segments from the low-expressing TG line (A) Representative blots from a TG/TG mouse after 1 month on doxycycline or a control littermate fed a doxycycline-free diet. Individual blots densities before and after doxycycline are shown in (B) Protein from each tubular segment was blotted for NCC, pNCC (pThr 58 ) and β actin (housekeeping protein) and plotted individually with the median values shown by the horizontal black bars. Presence ( + ) and absence ( − ) of doxycycline in the diet is indicated. Segments are: proximal and straight convoluted tubule (Prox), cortical thick ascending limb (CTAL), distal convoluted tubule (DCT), connecting tubule (CNT) and cortical collecting duct (CCD).
* P < 0.05 compared with non-doxycycline-dosed WT controls are real they may reflect compensatory changes in the nephron of the constitutive mouse to reduce the phenotypic impact of the Q562E mutation or differences in the methods used (invasive against BP measurement). Similar compensatory changes seem to occur in human subjects with Gordon's syndrome (PHAII), so that the phenotype of adults with the WNK4 Q565E mutation can be distinct from children even within the same pedigree [22] .
In our model, there was high-level expression of the TG following doxycycline activation particularly within the mouse with the highest high TG copy number. However, differences in TG expression did not translate into any obvious differences in the degree to which the BP or plasma K + levels increased on doxycycline activation of the TG. The BP in the high copy number line did not increase significantly on doxycycline, although the plasma K + levels did. The significant fall in BP off doxycycline suggests this lack of a significant BP increase may actually have been a false negative result. The lack of an obvious TG dose-effect is perhaps not surprising as Gordon's syndrome (PHAII) is an autosomal dominant condition and the phenotype emerges from more or less balanced levels of WT and mutant WNK4 transcripts in vivo. However, there was evidence for lowlevel constitutive TG activation in the mice with middle and high copy numbers (Figure 3 ). This leaky behaviour is well described for the Tet-On system, so future phenotypic work should probably focus on the low copy number line to reduce the impact of this leakiness. Nevertheless, the high levels of TG activation seen in our mice did not directly affect the level of Scl12a3 mRNA expression or lead to ectopic NCC expression in immunostained kidney sections (see Supplementary Figures at http://www.clinsci.org/cs/124/cs1240701add.htm). In fact, the level of NCC expression within microdissected DCT tubules in the mice with a low copy number was increased as expected and compares closely to the 2-fold increase reported in whole kidney blots from the D561A knock-in mouse model [7] .
In a previous constitutive transgenic mouse expressing the Q562E mutation, the adults showed obvious structural changes to their distal nephron with marked enlargement of the DCT lumens in kidney sections [6] . Even if the density of NCC at the apical membrane of these tubules were unchanged their increased surface area could substantially increase total Na + -Cl − co-transport through NCC. There are no reports of the histology of the kidney in human subjects with Gordon's syndrome (PHAII) to say whether similar morphological changes in the DCT occur in subjects carrying WNK4 mutations. However, similar changes were not seen in our transgenic mice at baseline or after after 4 weeks of TG induction. In fact, histological sections of the kidney from our mice after a month of doxycycline induction of the TG were indistinguishable from WT mice (see Supplementary Figure S2 at http://www.clinsci.org/cs/124/cs1240701add.htm). This makes it unlikely that the structural changes previously reported in mice constitutively expressing mutant WNK4 are important for a Gordon's syndrome (PHAII) phenotype.
There is now a large body of data showing that WNK4 does not work by simply phosphorylating NCC [23] . It actually sits within a signalling cascade and phosphorylates a downstream kinase called SPAK. Activated SPAK then phosphorylates key serine/threonine residues in the N-terminus of NCC causing its activation in vitro, and phosphorylation in vivo may be restricted to NCC inserted into the apical membrane of DCT cells. It also independently reduces forward trafficking of NCC from the Golgi by accelerating its lysosomal degradation [24] . This complexity to the molecular actions of WNK4 probably explains why a transgenic mouse overexpressing NCC can have a normal BP and normal plasma K + levels [9] . The emergence of the Gordon's syndrome (PHAII) phenotype must depend on both the expression level of NCC at the apical membrane, versus other subcellular compartments, and its phosphorylation state at the cell surface. It is relevant then that our mouse model shows increases in both NCC and the phospho-Thr 58 form of NCC after TG activation. Position 58 is thought to be the key residue for N-terminal phosphorylation and hence activation of NCC transporter activity [25] . We have previously shown that mice with a kinase-dead SPAK knocked-in are unable to phosphorylate this residue, so that SPAK appears to be the primary kinase for NCC in the DCT [17] . The resulting loss of NCC function produces a Gitelman-like phenotype that is the mirror image of Gordon's syndrome (PHAII).
We have not investigated whether shorter exposure times to doxycycline and hence TG activation would be as effective as the 4-week schedule chosen. However, there are useful clinical clues on this issue assuming TG activation and silencing parallels the time course of responses of subjects with Gordon's syndrome (PHAII) to a thiazide diuretic. The activated NCC transporter function caused by mutant WNK4 in these subjects makes affected subjects sensitive to even low doses of thiazide diuretics. In fact, the PHAII phenotype, especially the hyperkalaemia, resolves in 1-2 weeks of commencing treatment with a thiazide [5, 26] , and if the thiazide is discontinued reemerges within 2 weeks, presumably reflecting ongoing expression of mutant WNK4 protein [5] . So, our mouse model based on 4 weeks of TG activation producing a PHAII phenotype and its recovery within 4 weeks of silencing the TG recapitulates well the clinical behaviour of subjects with Gordon's syndrome (PHAII) exposed to a thiazide diuretic. Of course, transient expression of mutant WNK4 does have potential limitations. For example, mutant WNK4 expression does have effects outside of the kidney, such as a loss of bone mineral density that could reflect chronic or even lifelong hypercalciuria [5] . This has not been reported so far in any mouse model of Gordon's syndrome (PHAII), but clearly a model with only transient TG activation is not suited to explore this extended PHAII phenotype in the mouse.
In summary then, we have produced a robust inducible mouse model of the rare monogenic disorder, Gordon's syndrome (PHAII). The model shows that expression of mutant WNK4 is able to recapitulate the features of hypertension and hyperkalaemia after just 4 weeks of TG activation and that it is completely lost after a further 4 weeks of TG silencing. It should be useful in further exploration of the molecular physiology of the distal nephron in Gordon's syndrome (PHAII).
CLINICAL PERSPECTIVES
r The monogenic syndromes that cause familial hypertension are rare but unravelling their molecular basis has provided fundamental insights into how the distal nephron works. Gordon's syndrome (PHAII) is one of these monogenic syndromes. In the present paper, we report a new transgenic mouse model for the syndrome that is inducible by doxycycline.
r Inducing the TG causes expression of a mutant form of WNK4 leading to activation of the NCC transporter that is the usual target for thiazide diuretics in the kidney. This drives an increase in BP and plasma K + levels after 4 weeks that mimic closely those seen clinically in Gordon's syndrome (PHAII). It is reversed on withdrawal of the doxycycline for the same period and not accompanied by the morphological changes previously observed in a constitutively active transgenic model. r This model should be useful in gaining a better understanding of the molecular basis for Gordon's syndrome (PHAII) and its impact on the distal nephron.
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